Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment

A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear. People living with HIV from EuroSIDA with a known HCV status after January 2001 were cla...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Clinical infectious diseases Ročník 70; číslo 10; s. 2131
Hlavní autori:	Mocroft, Amanda, Lundgren, Jens, Gerstoft, Jan, Rasmussen, Line D, Bhagani, Sanjay, Aho, Inka, Pradier, Christian, Bogner, Johannes R, Mussini, Christina, Uberti Foppa, Caterina, Maltez, Fernando, Laguno, Montse, Wandeler, Gilles, Falconer, Karolin, Trofimova, Tatyana, Borodulina, Elena, Jevtovic, Djordje, Bakowska, Elzbieta, Kase, Kerstin, Kyselyova, Galina, Haubrich, Richard, Rockstroh, Jürgen K, Peters, Lars
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 06.05.2020
Predmet:	Carcinoma, Hepatocellular Coinfection - drug therapy Coinfection - epidemiology Hepacivirus Hepatitis C Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - epidemiology HIV HIV Infections - complications HIV Infections - drug therapy HIV Infections - epidemiology Humans Liver Neoplasms malignancies cardiovascular disease end-stage liver disease HIV hepatitis C
ISSN:	1537-6591, 1537-6591
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear. People living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures (HCV RNA-positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD). There were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1-13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0-6.9) for CVD, 6.5 (95% CI 6.1-6.9) for NADM, and 3.1 (95% CI 2.8-3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36-1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02-2.13) or treatment failure (aIRR 1.80, 95% CI 1.22-2.66) had significantly raised rates of ESLD, compared to those who were cured. Incidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining the importance of successful HCV treatment for reducing ESLD.
AbstractList	A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear.BACKGROUNDA hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear.People living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures (HCV RNA-positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD).METHODSPeople living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures (HCV RNA-positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD).There were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1-13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0-6.9) for CVD, 6.5 (95% CI 6.1-6.9) for NADM, and 3.1 (95% CI 2.8-3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36-1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02-2.13) or treatment failure (aIRR 1.80, 95% CI 1.22-2.66) had significantly raised rates of ESLD, compared to those who were cured.RESULTSThere were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1-13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0-6.9) for CVD, 6.5 (95% CI 6.1-6.9) for NADM, and 3.1 (95% CI 2.8-3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36-1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02-2.13) or treatment failure (aIRR 1.80, 95% CI 1.22-2.66) had significantly raised rates of ESLD, compared to those who were cured.Incidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining the importance of successful HCV treatment for reducing ESLD.CONCLUSIONSIncidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining the importance of successful HCV treatment for reducing ESLD. A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear. People living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures (HCV RNA-positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD). There were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1-13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0-6.9) for CVD, 6.5 (95% CI 6.1-6.9) for NADM, and 3.1 (95% CI 2.8-3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36-1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02-2.13) or treatment failure (aIRR 1.80, 95% CI 1.22-2.66) had significantly raised rates of ESLD, compared to those who were cured. Incidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining the importance of successful HCV treatment for reducing ESLD.
Author	Rasmussen, Line D Mocroft, Amanda Peters, Lars Maltez, Fernando Trofimova, Tatyana Uberti Foppa, Caterina Kyselyova, Galina Gerstoft, Jan Wandeler, Gilles Rockstroh, Jürgen K Lundgren, Jens Pradier, Christian Haubrich, Richard Bogner, Johannes R Falconer, Karolin Bakowska, Elzbieta Mussini, Christina Laguno, Montse Borodulina, Elena Kase, Kerstin Jevtovic, Djordje Bhagani, Sanjay Aho, Inka
Author_xml	– sequence: 1 givenname: Amanda surname: Mocroft fullname: Mocroft, Amanda organization: Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, United Kingdom – sequence: 2 givenname: Jens surname: Lundgren fullname: Lundgren, Jens organization: Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, and Department of Infectious Diseases, Copenhagen – sequence: 3 givenname: Jan surname: Gerstoft fullname: Gerstoft, Jan organization: Department of Infectious Diseases, Rigshospitalet, Copenhagen – sequence: 4 givenname: Line D surname: Rasmussen fullname: Rasmussen, Line D organization: Department of Infectious Diseases, Odense University Hospital, Denmark – sequence: 5 givenname: Sanjay surname: Bhagani fullname: Bhagani, Sanjay organization: Department of Infectious Diseases, Royal Free Hospital, London, United Kingdom – sequence: 6 givenname: Inka surname: Aho fullname: Aho, Inka organization: Division of Infectious Diseases, Helsinki University Hospital, Finland – sequence: 7 givenname: Christian surname: Pradier fullname: Pradier, Christian organization: Department of Public Health, Centre Hospitalier Universitaire de Nice, France – sequence: 8 givenname: Johannes R surname: Bogner fullname: Bogner, Johannes R organization: Division of Infectious Diseases, Medizinische Klinik und Poliklinik IV, Ludwig Maximilians University of Munich, Germany – sequence: 9 givenname: Christina surname: Mussini fullname: Mussini, Christina organization: Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Milan, Italy – sequence: 10 givenname: Caterina surname: Uberti Foppa fullname: Uberti Foppa, Caterina organization: Vita-Salute San Raffaele University, San Raffaele Scientific Institue, Clinic of Infectious Diseases, Milan, Italy – sequence: 11 givenname: Fernando surname: Maltez fullname: Maltez, Fernando organization: Hospital de Curry Cabral, Serviço de Doenças Infecciosas, Lisbon, Portugal – sequence: 12 givenname: Montse surname: Laguno fullname: Laguno, Montse organization: Infectious Diseases Service, Hospital Clinic-L'Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Spain – sequence: 13 givenname: Gilles surname: Wandeler fullname: Wandeler, Gilles organization: Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland – sequence: 14 givenname: Karolin surname: Falconer fullname: Falconer, Karolin organization: Infectious Diseases Department, Karolinska University Hospital, Stockholm, Sweden – sequence: 15 givenname: Tatyana surname: Trofimova fullname: Trofimova, Tatyana organization: Novgorod Centre for Acquired Immunodeficiency Syndrome Prevention and Control, Novgorod the Great, Russia – sequence: 16 givenname: Elena surname: Borodulina fullname: Borodulina, Elena organization: Samara State Medical University, Russia – sequence: 17 givenname: Djordje surname: Jevtovic fullname: Jevtovic, Djordje organization: Belgrade University School of Medicine, Infectious & Tropical Diseases Hospital, Serbia – sequence: 18 givenname: Elzbieta surname: Bakowska fullname: Bakowska, Elzbieta organization: Wojewodzki Szpital Zakazny, Warsaw, Poland – sequence: 19 givenname: Kerstin surname: Kase fullname: Kase, Kerstin organization: Centre of Infectious Diseases, West-Tallin Central Hospital, Tallin, Estonia – sequence: 20 givenname: Galina surname: Kyselyova fullname: Kyselyova, Galina organization: Crimean Republican Acquired Immunodeficiency Syndrome Centre, Simferopol – sequence: 21 givenname: Richard surname: Haubrich fullname: Haubrich, Richard organization: Gilead Sciences Inc., Foster City, California – sequence: 22 givenname: Jürgen K surname: Rockstroh fullname: Rockstroh, Jürgen K organization: Department of Medicine, University Hospital Bonn, Germany – sequence: 23 givenname: Lars surname: Peters fullname: Peters, Lars organization: Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Copenhagen, and Department of Infectious Diseases, Copenhagen
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31504296$$D View this record in MEDLINE/PubMed
BookMark	eNplkM1KxDAUhYOMOD-68QEkSzfVpGnTxp0M6gwMjItRlyVJbzDSpLVJF-MD-NwWZgTBxeUezvnuWdw5mvjWA0KXlNxQItittvU4X5zQEzSjOSsSngs6-aOnaB7CByGUliQ_Q1NGc5Klgs_Q97Kx3mrZ4O0QdesgYOvxM_Sh9QEvW-sN6Ag1frPxHa8GJz1eOzf4tgZjtQWv9_jV9kPA0td4BZ2MNtrx9ODejXQndcSt-R_iXQ8yOvDxHJ0a2QS4OO4Fenl82C1XyWb7tF7ebxLNOI0JE0owaXQGhUlLxYDSvGR1TUyhMqF0WXJVZDLPVCaBGAWCcZLzjAlpWKp5ukDXh96ubz8HCLFyNmhoGumhHUKVpmVZ0JJTNqJXR3RQDuqq662T_b76_V36AziGc8M
CitedBy_id	crossref_primary_10_1016_j_jiph_2025_102654 crossref_primary_10_1097_QAD_0000000000003406 crossref_primary_10_1177_10783903221115741 crossref_primary_10_1186_s12879_021_06003_z crossref_primary_10_1097_QAI_0000000000002541 crossref_primary_10_1097_QAD_0000000000003112 crossref_primary_10_1097_QAD_0000000000003594 crossref_primary_10_1097_QAD_0000000000002570 crossref_primary_10_3389_fmicb_2021_731337
ContentType	Journal Article
Contributor	Dragovic, G Chkhartishvili, N Gottfredsson, M Mulcahy, F Clumeck, N Rozentale, B Schmied, B Staub, T Karpov, I Viard, J-P Reikvam, D H Caldeira, L Aho, I Gazzard, B Machala, L Knysz, B Szlávik, J Radoi, R Uzdaviniene, V Falconer, K Panteleev, A Hadziosmanovic, V Reiss, P Sambatakou, H Scherrer, A Rockstroh, J Tau, L Begovac, J Zilmer, K Tomazic, J Miró, J M Losso, M D'Arminio Monforte, A
Contributor_xml	– sequence: 1 givenname: M surname: Losso fullname: Losso, M – sequence: 2 givenname: B surname: Schmied fullname: Schmied, B – sequence: 3 givenname: I surname: Karpov fullname: Karpov, I – sequence: 4 givenname: N surname: Clumeck fullname: Clumeck, N – sequence: 5 givenname: V surname: Hadziosmanovic fullname: Hadziosmanovic, V – sequence: 6 givenname: J surname: Begovac fullname: Begovac, J – sequence: 7 givenname: L surname: Machala fullname: Machala, L – sequence: 8 givenname: K surname: Zilmer fullname: Zilmer, K – sequence: 9 givenname: I surname: Aho fullname: Aho, I – sequence: 10 givenname: J-P surname: Viard fullname: Viard, J-P – sequence: 11 givenname: J surname: Rockstroh fullname: Rockstroh, J – sequence: 12 givenname: N surname: Chkhartishvili fullname: Chkhartishvili, N – sequence: 13 givenname: H surname: Sambatakou fullname: Sambatakou, H – sequence: 14 givenname: J surname: Szlávik fullname: Szlávik, J – sequence: 15 givenname: M surname: Gottfredsson fullname: Gottfredsson, M – sequence: 16 givenname: F surname: Mulcahy fullname: Mulcahy, F – sequence: 17 givenname: L surname: Tau fullname: Tau, L – sequence: 18 givenname: A surname: D'Arminio Monforte fullname: D'Arminio Monforte, A – sequence: 19 givenname: B surname: Rozentale fullname: Rozentale, B – sequence: 20 givenname: V surname: Uzdaviniene fullname: Uzdaviniene, V – sequence: 21 givenname: T surname: Staub fullname: Staub, T – sequence: 22 givenname: P surname: Reiss fullname: Reiss, P – sequence: 23 givenname: D H surname: Reikvam fullname: Reikvam, D H – sequence: 24 givenname: B surname: Knysz fullname: Knysz, B – sequence: 25 givenname: L surname: Caldeira fullname: Caldeira, L – sequence: 26 givenname: R surname: Radoi fullname: Radoi, R – sequence: 27 givenname: A surname: Panteleev fullname: Panteleev, A – sequence: 28 givenname: G surname: Dragovic fullname: Dragovic, G – sequence: 29 givenname: J surname: Tomazic fullname: Tomazic, J – sequence: 30 givenname: J M surname: Miró fullname: Miró, J M – sequence: 31 givenname: K surname: Falconer fullname: Falconer, K – sequence: 32 givenname: A surname: Scherrer fullname: Scherrer, A – sequence: 33 givenname: B surname: Gazzard fullname: Gazzard, B
Copyright	The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Copyright_xml	– notice: The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
CorporateAuthor	EuroSIDA Study
CorporateAuthor_xml	– name: EuroSIDA Study
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/cid/ciz601
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1537-6591
ExternalDocumentID	31504296
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- ..I .2P .I3 .ZR 08P 0R~ 29B 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 70D AABZA AACGO AACZT AAJKP AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPLY ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEUPB AEWNT AFFZL AFIYH AFOFC AFRAH AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN AQKUS ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EMOBN ENERS ESX F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HW0 HZ~ IOX J21 JLS JSG KAQDR KBUDW KOP KSI KSN L7B M49 MHKGH MJL ML0 N9A NGC NOMLY NOYVH NPM NU- O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y RD5 ROX ROZ RUSNO RW1 RXO SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- 7X8 ABPQP ADNBA AEMQT AFYAG AHGBF AJBYB AJNCP ALXQX JXSIZ
ID	FETCH-LOGICAL-c361t-39b93afc4e7f28b3e11583dd0f7b49bc886b74a54b4ae0fbe936056439af32c62
IEDL.DBID	7X8
ISICitedReferencesCount	13
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000551492200020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1537-6591
IngestDate	Wed Oct 01 13:14:04 EDT 2025 Wed Feb 19 02:30:01 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	10
Keywords	malignancies cardiovascular disease end-stage liver disease HIV hepatitis C
Language	English
License	The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c361t-39b93afc4e7f28b3e11583dd0f7b49bc886b74a54b4ae0fbe936056439af32c62
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://academic.oup.com/cid/article-pdf/70/10/2131/33174494/ciz601.pdf
PMID	31504296
PQID	2288718613
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2288718613 pubmed_primary_31504296
PublicationCentury	2000
PublicationDate	2020-05-06
PublicationDateYYYYMMDD	2020-05-06
PublicationDate_xml	– month: 05 year: 2020 text: 2020-05-06 day: 06
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Clinical infectious diseases
PublicationTitleAlternate	Clin Infect Dis
PublicationYear	2020
References	31265062 - Clin Infect Dis. 2020 May 6;70(10):2141-2142
References_xml	– reference: 31265062 - Clin Infect Dis. 2020 May 6;70(10):2141-2142
SSID	ssj0011805
Score	2.4230547
Snippet	A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	2131
SubjectTerms	Carcinoma, Hepatocellular Coinfection - drug therapy Coinfection - epidemiology Hepacivirus Hepatitis C Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - epidemiology HIV HIV Infections - complications HIV Infections - drug therapy HIV Infections - epidemiology Humans Liver Neoplasms
Title	Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment
URI	https://www.ncbi.nlm.nih.gov/pubmed/31504296 https://www.proquest.com/docview/2288718613
Volume	70
WOSCitedRecordID	wos000551492200020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7UinhxX-rGCF6DTWayjBeRYqlgaw-19hZmxYAktUk9-AP83b7JQg8iCF5ySDIhvHlv3vd2hK46IDIkML4TUiUcyhRzOPeYnfWiBAX7WZd13JPHcDiMplM2qh1ueZ1W2ZyJ5UGtMml95NeeB-LgRqB9bmfvjp0aZaOr9QiNVdQiAGUsV4fTZRTBjcoURhDq0Al85jbtSRm5lrDVMvkMOu7v0LJUMb3t__7cDtqqwSW-q7hhF63odA9tDOrw-T76qruAvuGnRQFf1jlOUjwqQXeOu1mVmaUVfkmKV1z69_GDLSDJlLadJmyZJp4k80WOeapwX9t07CKBpdXdG3jbFl3izPx8iMdNTvsBeu7dj7t9px7E4EgSuIVDmGCEG0l1aLxIEA0wMiJKdUwoKBMyigIRUu5TQbnuGKEZASvJYh1uiCcD7xCtpVmqjxE21GdG2ikMXFIwtSJJje9LpXwqJSG6jS4bCsfA6DZ6wVOdLfJ4SeM2Oqq2KZ5VHTliArAWFGtw8ofVp2jTszazTVoMzlDLgJjrc7QuP4Ak84uSg-A6HA2-Ac2G00o
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Outcomes+in+Persons+Coinfected+With+Human+Immunodeficiency+Virus+and+Hepatitis+C+Virus%3A+Impact+of+Hepatitis+C+Virus+Treatment&rft.jtitle=Clinical+infectious+diseases&rft.au=Mocroft%2C+Amanda&rft.au=Lundgren%2C+Jens&rft.au=Gerstoft%2C+Jan&rft.au=Rasmussen%2C+Line+D&rft.date=2020-05-06&rft.issn=1537-6591&rft.eissn=1537-6591&rft.volume=70&rft.issue=10&rft.spage=2131&rft_id=info:doi/10.1093%2Fcid%2Fciz601&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon